To assess the feasibility, acceptability, and preliminary effects of a nurse-led intervention for managing fear of cancer progression in advanced cancer patients. (Source: European Journal of Oncology Nursing)
We report results from three intensive 6-h communication workshops held for 69 UK specialist breast care nurses (SBCNs). The one-day workshops aimed to help participants explain Oncotype DX Breast Recurrence Score ® results (RSs) to patients and contained three primary elements from the evidence-based TARGET (Talking About Risk in the Context of Genomic Tests) programme shown to enhance knowledge acquisition, skills development and self-awareness [Fallowfield et al., 2019]. Important features were...
To investigate the degree of concordance on fatigue assessment between children and adolescents with cancer and their parents, and its changes over time. (Source: European Journal of Oncology Nursing)
To conduct an integrative scoping review of the physical, psychological and social experiences of women who have experienced chemotherapy-induced alopecia (CIA). (Source: European Journal of Oncology Nursing)
This study explored main consider ations for palliative health-care professionals in these situations, and how they negotiate conflicting considerations of confidentiality and child involvement. (Source: European Journal of Oncology Nursing)
This study aims to comp are the costs of providing cancer support services in a day-ward versus in the community. (Source: European Journal of Oncology Nursing)
Mark above section as read
The article Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3, (Source: Targeted Oncology)
AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness. While recent treatment advancements have extended overall survival (OS), refractory MM has a poor prognosis, with a median OS of between 4 and 6 months. Nuclear export inhibition, specifically inhibition of CRM1/XPO1, is an emerging novel treatment modality that has shown promise in treatment-refractory MM. Initially discovered in yeast in...
ConclusionsMonotherapy with sunitinib does not have clinical activity in patients with mCRC withFLT-3 amplification and should not be prescribed for off-label use. Other treatments should be considered for these patients, including treatments offered in clinical trials.Clinical Trial registrationNCT02693535 (26 February 2016). (Source: Targeted Oncology)
ConclusionsAnti-EGFR rechallenge provides clinical benefit in patients withRAS wild-type metastatic CRC. (Source: Targeted Oncology)
ConclusionsOur analysis identified baseline blood eosinophil counts as a new prognostic factor in patients with sorafenib-treated hepatocellular carcinoma. Concerning second-line therapies, eosinophil counts were associated with survival outcomes only in regorafenib-treated patients, suggesting a possible predictive role in this setting. (Source: Targeted Oncology)
ConclusionsThese results support a conclusion of similar clinical efficacy between ABP 798 and rituximab RP in patients with follicular lymphoma.NCT NumberNCT02747043; first posted April 21, 2016.EudraCT Number2013-005,542-11; submitted 14 October, 2014. (Source: Targeted Oncology)
AbstractGenomic instability is one of the hallmarks of cancer. The incidence of genetic alterations in homologous recombination repair genes increases during cancer progression, and 20% of prostate cancers (PCas) have defects in DNA repair genes. Several somatic and germline gene alterations drive prostate cancer tumorigenesis, and the most important of these areBRCA2,BRCA1,ATM andCHEK2. There is a group of BRCAness tumours that share phenotypic and genotypic properties with classicalBRCA-mutated...
ConclusionsBoth the survival period and risk factors were extracted from a relatively long-term observation period. Since enzalutamide was approved for administration to patients with castration-sensitive prostate cancer earlier this year (2020), we believe that the data presented here will be useful for both physicians and patients in clinical practice. (Source: Targeted Oncology)
ConclusionsCPD0857 may be a potential drug for treating aggressive CRC carrying mutations that aberrantly activate Wnt/ β-catenin and Ras-ERK pathways. (Source: Targeted Oncology)
ConclusionDespite the good tolerance, palbociclib monotherapy did not show favorable efficacy against recurrent AO.Trial RegistrationThis study is registered with ClinicalTrials.gov, identifier NCT0253032 (retrospectively registered on 21 August 2015). (Source: Targeted Oncology)
AbstractPancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl, MerTK) is directly implicated in the pathogenesis of the metastatic, chemoresistant, and immunosuppressive phenotype in pancreatic cancer. TAM inhibitors are promising investigational therapies...
ConclusionsETS and DpR serve as surrogate markers of PFS and OS in the second-line treatment with FOLFIRI plus targeted agent for mCRC. (Source: Targeted Oncology)
AbstractGilteritinib (Xospata®), a next-generation tyrosine kinase inhibitor (TKI), is approved in several countries/regions worldwide for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in adults with FMS-like tyrosine kinase 3 (FLT3) mutations. In this patient population, oral gilteritinib significantly improved overall survival (OS) and the response rate for complete remission with full or partial haematological recovery compared with salvage chemotherapy in the phase III...
Mark above section as read
The MammaPrint 70-gene signature has similar prognostic performance in women with early-stage invasive lobular carcinoma and invasive ductal carcinoma (IDC), according to an exploratory analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Turning in-person medical meetings into online events in the wake of the pandemic levelled the playing field for people who haven't traditionally had access to such meetings.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Dr Mark Kris discusses how recent data presented at ESMO continue to support osimertinib as an important drug in the adjuvant setting for patients with completely resected EGFR-mutant lung cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
As COVID-19 cases continue to increase or increase again worldwide, Medscape reached out to oncologists in different countries to hear how they are preparing and what they learned from the first wave.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Brexucabtagene autoleucel (Tecartus) is a new cell therapy product and the only one with an indication for this particular hematological malignancy.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Far too often, online discussions among oncologists cross the line into specious and even dangerous territory.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Dr David Kerr discusses recent data on phosphodiesterase-5 inhibitor use in patients with colorectal cancer, and his own experience with Viagra.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Surveillance with carcinoembryonic antigen testing and CT scans after colorectal cancer resection did not improve survival when compared with standard abdominal ultrasound and chest x-ray monitoring.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Adding systemic chemotherapy with temozolomide to radiotherapy offers a significant survival benefit over radiotherapy alone, study findings indicate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Cancer researchers are contributing to the development and repurposing of drugs for the treatment of COVID-19, particularly for cytokine storm.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Increased deaths due to heart disease and Alzheimer's disease or dementia also increased as a result of the COVID-19 pandemic, research shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
When compared with a delay of less than 3 months, the longer delay seen this year may result in an 11.9% increase in death rates.WebMD Health News (Source: Medscape Hematology-Oncology Headlines)
A family physician with an interest in cancer medicine reviews Dr Vinay Prasad's latest book, Malignant.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Mortality in patients with COVID-19 and cancer is associated with general clinical and demographic factors, cancer-specific factors, cancer treatment variables, and laboratory parameters.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Dr David Kerr discusses four studies that caught his eye at this year's virtual ESMO meeting.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Acalabrutinib, alone or in combination with obinutuzumab, showed favorable progression-free survival and overall survival compared with other frontline therapies for chronic lymphocytic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
New data show morbidity and mortality rates from COVID-19 are similar for individuals with or without cancer, suggesting that cancer care can be continued despite the pandemic.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Restarting breast cancer screening programs after the COVID-19 disruption will be challenging given a trade-off between minimizing excess mortality and strain on programs, according to a modeling study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
In contrast with previous studies, a new analysis finds a lower risk of suicidal behaviors and suicide-related death among survivors compared with controls.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
The abscopal effect, whereby tumors are reduced or eliminated even though they are situated outside the radiation field, was first described in the 1950s. But is it largely the result of chance?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Lymphoma specialist Ann LaCasce, MD, discusses tafasitamab-cxix, the recently approved treatment for patients with relapsed/refractory disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Dr Mikkael Sekeres discusses how the recent ASH guidelines, on which he is a coauthor, are meant to guide the difficult decisions that follow a new diagnosis of AML in older patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Combination nivolumab and ipilimumab has now been approved as first-line treatment in mesothelioma and possibly a new standard of care.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
The diagnosis of acute lymphoblastic leukemia (ALL) can be delayed because of vague presentation and normal hematological results.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Three physicians, one of whom has incurable cancer, argue that it is time for a fresh debate on medically assisted dying in the UK, where the practice is illegal.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
A review from Sweden of more than 1 million girls/women vaccinated in 2006 – 2017 shows a substantial reduction in the risk for invasive cervical cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Details of the data that led to FDA approval of tumor mutation burden (TMB) as a biomarker for pembrolizumab use in advanced cancers have now been published.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Physicians can recommend that patients receive hospice care when they have less than 6 months to live; but what if their prognosis is not accurate? Are doctors at risk?Medscape Business of Medicine (Source: Medscape Hematology-Oncology Headlines)
A new meta-analysis has largely confirmed what is already known about lifestyle factors that increase or lower the risk for colorectal cancer (CRC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
"There is...a need for our nation's leaders to take on a much bigger role in confronting and combat-ing the structural and systemic racism that contributes to health disparities," says the AACR.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Certain patients with triple-negative breast cancer (TNBC) may benefit when atezolizumab is combined with nab-paclitaxel but not with paclitaxel, a pair of phase 3 trials suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
The former head of Florida Cancer Specialists has been indicted by a federal grand jury for conspiring to restrict cancer patients'choice of a treatment provider.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Patients with higher intraoperative blood loss and those treated at lower-volume surgical centers had a greater risk of high-grade complications after undergoing CN for mRCC, according data analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
The most common form of liver cancer has seen a demographic shift, with incidence highest in the Hispanic population. The good news in HCC is that rates appear to be declining among young men.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Michael Caputo, who is on leave from his role as spokesperson for the U.S. Department of Health and Human Services after accusing government scientists of sedition, has metastatic cancer, a state lawmaker said.Associated Press (Source: Medscape Hematology-Oncology Headlines)
If you have participated in a virtual medical meeting this year, tell us about your experience.Medscape Reader Polls (Source: Medscape Hematology-Oncology Headlines)
Why are results so different between IMpassion130 and IMpassion131? There is no clear answer, says Dr Kathy Miller.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
The checkpoint inhibitor prolonged progression-free survival in patients with four subtypes of metastatic or unresectable locally advanced sarcomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
First-line lorlatinib significantly prolonged progression-free survival compared with crizotinib in advanced ALK-positive nonsmall cell lung cancer, according to a phase 3 interim analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
An advisory group to the National Cancer Institute is reviewing the"feasibility and relevance" of the ongoing TMIST trial that is comparing 3-D to 2-D mammography and is asking if it should continue.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου